Biotechnology News and Research

RSS

Baxter enters definitive agreement to acquire Baxa

Baxter International Inc. announced today that it has entered into a definitive agreement to acquire Baxa Corporation, a privately held company based in Englewood, Colo., with additional operations in Florida and the United Kingdom.

From Baxter International Inc. 25 Aug 2011

TB urine test developed by Indian researchers offers quicker, less invasive diagnosis

"The Delhi-based International Centre for Genetic Engineering and Biotechnology (ICGEB) and the Lala Ram Sarup Institute of Tuberculosis and Respiratory Diseases, collaborated with the National University of Singapore to develop" a urine test that "offers a less invasive diagnostic method for" tuberculosis (TB), SciDev reports.

25 Aug 2011

New mouse brain atlas provides insight into how genes work in cerebral cortex

A new atlas of gene expression in the mouse brain provides insight into how genes work in the outer part of the brain called the cerebral cortex. In humans, the cerebral cortex is the largest part of the brain, and the region responsible for memory, sensory perception and language.

25 Aug 2011

Researchers discover NPC1 protein as crucial for Ebola virus to enter host cells

Although outbreaks are rare, Ebola virus, the cause of Ebola hemorrhagic fever (EHF), is one of the deadliest known viruses affecting humans. According to the World Health Organization (WHO), approximately 1,850 EHF cases with more than 1,200 deaths have been documented since the virus was identified in 1976.

25 Aug 2011

Kibow renews exclusive worldwide veterinary licensing and marketing agreement

Kibow Biotech, Inc. today announced that it has renewed its exclusive worldwide licensing and marketing agreement with the current licensing partner specializing in animal health.

24 Aug 2011

DATATRAK announces addition of eClinical Consulting Group to Connect Partner Program

DATATRAK International, Inc., a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced the newest member of its Connect Partner Program, eClinical Consulting Group.

24 Aug 2011

United Therapeutics completes treprostinil diethanolamine Phase 3 trial in PAH

United Therapeutics Corporation announced today the completion of its FREEDOM-C(2) Phase 3 trial of treprostinil diethanolamine, an investigational sustained release oral formulation of treprostinil, a stable synthetic form of prostacyclin, in patients with pulmonary arterial hypertension.

24 Aug 2011

Insight into acrolein-induced acute lung injury

Metabolon, Inc., the leader in metabolomics, biomarker discovery and biochemical analysis, announces the publication of "Integrative Metabolome and Transcriptome Profiling Reveals Discordant Energetic Stress Between Mouse Strains with Differential Sensitivity to Acrolein-Induced Acute Lung Injury" in The Molecular Nutrition and Food Research Journal.

24 Aug 2011

Seattle Genetics initiates ADCETRIS phase II trial in CD30-positive non-Hodgkin lymphoma

Seattle Genetics, Inc. today announced that it has initiated a phase II clinical trial of ADCETRIS for patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas, including diffuse large B-cell lymphoma, peripheral T-cell lymphoma and other less common lymphoma subtypes.

24 Aug 2011

Bullet proof skin from human cells and spider silk

Dutch artist Jalila Essaidi, along with Utah State researcher Randy Lewis have made a swatch of nearly bulletproof skin made from spider silk and human skin cells. The project called “2.6g 329m/s” takes its name from the maximum weight and velocity a Type 1 bulletproof vest can withstand from a .22 calibre Long Rifle bullet.

23 Aug 2011

Hutchinson Center to participate in NCI-funded proteome research consortium

The National Cancer Institute today announced that a team co-led by Fred Hutchinson Cancer Research Center and The Broad Institute in Cambridge, Mass., has been selected to participate in a National Cancer Institute-funded research consortium dedicated to understanding the molecular basis of cancer.

23 Aug 2011

Spinifex secures AU$6.25 million in expanded Series B funding

Spinifex Pharmaceuticals, an Australian pain drug development company, today announced it has secured a further AU$6.25 million of venture capital investment from GBS Venture Partners Limited, Brandon Capital Partners Pty Limited, Uniseed Management Pty Limited and UniQuest Pty Limited to fund the development of its pain management drug, EMA401.

23 Aug 2011

NextDocs receives $10.3 million in Series A financing

NextDocs Corporation, the global leader in Microsoft SharePoint based software solutions for life sciences industries, today announced that the Company has received $10.3 million in a Series A financing from OpenView Venture Partners.

23 Aug 2011

Fibrocell Science announces completion of $22.8M private placement

Fibrocell Science, Inc. announced today that the Company has completed a private placement with certain accredited investors, pursuant to which the Company sold to the purchasers an aggregate of 41,409,458 shares of Company common stock at a purchase price of $0.55 per share.

23 Aug 2011

NovaDel, Rechon enter license and distribution agreement for Zolpimist

NovaDel Pharma Inc., a specialty pharmaceutical company that develops oral spray formulations of marketed pharmaceutical products, today announced its entry into an exclusive license and distribution agreement with Rechon Life Science AB to manufacture and commercialize Zolpimist® outside the United States and Canada. Zolpimist is our oral spray formulation of zolpidem tartrate approved by the FDA in December of 2008.

23 Aug 2011

Federal Circuit affirms dismissal of Illumina's patent infringement lawsuits against Affymetrix

Affymetrix, Inc. today announced that the U. S. Court of Appeals for the Federal Circuit has affirmed the dismissal of the patent infringement lawsuits brought against the Company by Illumina regarding U.S. Patent Nos. 7,510,841 and 7,612,020.

From Illumina, Inc. 22 Aug 2011

Scientists reveal how thiostrepton blocks FOXM1 protein, prevents breast cancer development

Scientists have discovered how a molecule that was first discovered in bacteria blocks a protein which causes breast cancer to develop and spread, reveals research published in Nature Chemistry today.

22 Aug 2011

EBD Group, MassBio announce plenary sessions program for BioPharm America 2011

EBD Group and MassBio today announced the plenary sessions program for BioPharm America 2011, being held at the Westin Boston Waterfront Hotel, September 7-9.

20 Aug 2011

FDA approves Seattle Genetics ADCETRIS drug to treat Hodgkin lymphoma, ALCL

Seattle Genetics, Inc. today announced that the U.S. Food and Drug Administration has granted accelerated approval of ADCETRISTM for two indications: (1) the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates, and (2) the treatment of patients with systemic anaplastic large cell lymphoma after failure of at least one prior multi-agent chemotherapy regimen.

20 Aug 2011

NIH approves BioTime's four GMP human embryonic stem cell lines

BioTime, Inc., a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that four human embryonic stem (hES) cell lines: ESI-035, ESI-049, ESI-051 and ESI-053, developed by a BioTime subsidiary have been approved by the National Institutes of Health (NIH) for inclusion in the NIH Human Embryonic Stem Cell Registry.

20 Aug 2011